J. Robert Coleman, PhD | American Lung Association

Location Select your location

J. Robert Coleman, PhD

Research Awards Nationwide Recipient (2013-2015)

State University of New York, Farmingdale, NY
Funded in Partnership with support from the Mary Fuller Russell Research Fund
New Streptococcus Pneumonia Vaccine Would Protect Against All Strains

Streptococcus pneumonia (SP) is the leading cause of bacterial pneumonia in the United States and worldwide. There are two current vaccines for SP—one for adults and one for children. However, each is limited as neither vaccine protects against all 92 strains of SP that have emerged and caused disease in susceptible populations. Dr. Coleman and his team have begun to genetically redesign genes shared by all 92 serotypes to construct a "universal" vaccine to produce a weakened strain that over-expresses "protective" proteins. Some in the pneumococcal field have suggested that a whole-cell/live vaccine approach may be the most promising avenue to achieve 92-serotype protection and their project pursues this approach.

Ask An Expert

Questions about your lung health? Need help finding healthcare? Call 1-800-LUNGUSA.

Get help
We need your generous support

Make a difference by delivering research, education and advocacy to those impacted by lung disease.

What is LUNG FORCE?

LUNG FORCE unites women and their loved ones across the country to stand together in the fight against lung cancer.

Get involved
Join the fight for healthy lungs and healthy air.
Donate Now.